Marker Therapeutics, Inc. (MRKR) Cash Flow Statement

The frequent divergence between net income and operating cash flow indicates that the company's reported losses do not fully capture the immediate liquidity impact of its R&D-heavy operations. Investors should monitor these fluctuations as they suggest that the timing of clinical trial expenditures and grant-related inflows creates significant noise in the cash flow statement.

The lack of a positive FCF trajectory underscores the company's status as a pre-revenue entity where cash burn is the primary operational metric. The absence of any meaningful FCF margin improvement suggests that the company remains entirely dependent on capital markets to bridge the gap until potential commercialization.

These swings in working capital appear to be driven by the timing of clinical site payments and potential milestone-based grant receipts rather than operational efficiency. This volatility complicates cash forecasting and suggests that the company's liquidity position is highly sensitive to the timing of specific trial-related obligations.